Ocuphire Pharma, Inc.
News
UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Globe Newswire Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following...\n more…
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Globe Newswire Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following...\n more…
Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher
Simply Wall St Celebrations may be in order for Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders, with the analysts delivering a...\n more…
Canaccord Genuity Group Reaffirms Buy Rating for Ocuphire Pharma (NASDAQ:OCUP)
Ticker Report Canaccord Genuity Group restated their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP - Free Report) in a report released on Wednesday morning, Benzinga reports. The firm currently has a $18.00...\n more…
HC Wainwright Lowers Ocuphire Pharma (NASDAQ:OCUP) Price Target to $18.00
Ticker Report Ocuphire Pharma (NASDAQ:OCUP - Get Free Report) had its price target cut by investment analysts at HC Wainwright from $20.00 to $18.00 in a research report issued to clients and investors on...\n more…
Ocuphire Pharma, Inc. Forecasted to Post Q3 2024 Earnings of ($0.30) Per Share (NASDAQ:OCUP)
Ticker Report Ocuphire Pharma, Inc. (NASDAQ:OCUP - Free Report) - Research analysts at HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for shares of Ocuphire Pharma in a report issued on...\n more…